Compare SINT & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | EDSA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.3M |
| IPO Year | 2014 | N/A |
| Metric | SINT | EDSA |
|---|---|---|
| Price | $2.84 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $13.00 |
| AVG Volume (30 Days) | 35.8K | ★ 95.6K |
| Earning Date | 03-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $80.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.94 |
| 52 Week High | $7.36 | $4.49 |
| Indicator | SINT | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 24.47 | 30.21 |
| Support Level | $3.53 | $0.94 |
| Resistance Level | $3.94 | $1.34 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 6.32 | 31.63 |
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.